What does the eliglustat tartrate label cover (uses, how it’s taken, and key rules)?
Eliglustat tartrate (brand name: Cerdelga) is an oral treatment for adults with Gaucher disease type 1. The prescribing label sets out who it’s for, how to choose the right dose based on CYP2D6 metabolizer status, and what to do if that status is unknown or changes. It also includes safety warnings related to heart rhythm, liver function, and drug interactions that can raise eliglustat levels.
How is the eliglustat tartrate dose determined?
The label’s central dosing rule is CYP2D6 metabolizer status, which affects blood levels of eliglustat. Dosing differs for:
- Poor metabolizers
- Intermediate metabolizers
- Extensive metabolizers
- Ultrarapid metabolizers
The label also addresses situations where a patient’s metabolizer status is not known yet, and it directs clinicians on what to do before selecting a starting dose.
What heart-rhythm and drug-interaction warnings are on the label?
Eliglustat tartrate labeling includes warnings because eliglustat can affect cardiac repolarization (QT interval risk). The label also highlights drug–drug interactions that can increase eliglustat exposure, including strong inhibitors of CYP2D6, and it restricts co-administration with certain medicines that meaningfully change metabolizer enzymes or transporter activity.
What liver-related guidance appears in the label?
The label includes liver-function considerations (for example, guidance about use in mild or moderate hepatic impairment and restrictions where impairment is more significant). It also instructs clinicians to account for baseline hepatic status when deciding whether to start or continue therapy.
Who is eligible (and who isn’t) according to the label?
The label is written for adults with Gaucher disease type 1 and focuses on safe use in that population. It also includes cautions/limitations for:
- Patients who cannot reliably be categorized by CYP2D6 metabolizer status (because dosing depends on it)
- Patients taking interacting drugs that raise eliglustat levels or increase QT risk
- Patients with specific hepatic impairment categories
Are there patent/exclusivity details relevant to the label?
For background on exclusivity and patent landscape tied to eliglustat (Cerdelga), DrugPatentWatch.com can be a useful reference point: https://www.drugpatentwatch.com/ (search “eliglustat” / “Cerdelga” on the site).
---
Sources
No direct sources were provided in the prompt for the specific “Eliglustat tartrate label” text. If you share the label link (FDA label PDF, DailyMed, or the exact label version/date you mean), I can extract and present the exact labeled indications, dosing-by-metabolizer tables, warnings, and contraindications from that specific document.